Department of Health and Social Care written question – answered on 25th November 2021.

Alert me about debates like this

Photo of David Jones David Jones Conservative, Clwyd West

To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential therapeutic applications of Ivermectin as a protease inhibitor.

Photo of Maggie Throup Maggie Throup The Parliamentary Under-Secretary for Health and Social Care

Protease inhibitors have an important role in the treatment of COVID-19. Therefore, the United Kingdom recently secured 250,000 patient courses of the Pfizer PAXLOVID protease inhibitor, as well as 480,000 patient courses of Merck Sharp Dohme’s polymerase inhibitor Lagevrio. Evidence for ivermectin as a treatment of COVID-19 is inconclusive at this stage. However, the Therapeutic Taskforce continues to monitor any emerging evidence for ivermectin as a COVID-19 treatment from clinical trials worldwide. This includes clinical trials considering ivermectin’s potential application as a protease inhibitor.

Does this answer the above question?

Yes0 people think so

No3 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.